Innoviva, Inc. Files Definitive Proxy Statement (DEF 14A)

TL;DR

<b>Innoviva, Inc. has filed its Definitive Proxy Statement (DEF 14A) detailing corporate governance and executive compensation information.</b>

AI Summary

Innoviva, Inc. (INVA) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Innoviva, Inc. filed a DEF 14A form on April 29, 2024. The filing covers the period ending June 17, 2024. The company's principal executive offices are located at 1350 Old Bayshore Highway, Suite 400, Burlingame, CA 94010. Innoviva, Inc. was formerly known as Theravance Inc. and Advanced Medicine Inc. The SIC code for the company is 2834 (Pharmaceutical Preparations).

Why It Matters

For investors and stakeholders tracking Innoviva, Inc., this filing contains several important signals. This filing is crucial for shareholders to understand executive compensation structures and make informed voting decisions at the upcoming shareholder meeting. The DEF 14A provides transparency into the company's governance practices, including details on equity awards and their valuation, which can impact shareholder value.

Risk Assessment

Risk Level: low — Innoviva, Inc. shows low risk based on this filing. The filing is a routine DEF 14A, which is standard for public companies and does not contain new financial performance data or significant strategic shifts.

Analyst Insight

Shareholders should review the executive compensation details and any proposed governance changes to inform their voting decisions.

Key Numbers

• 2834 — SIC Code (Standard Industrial Classification)
• 1231 — Fiscal Year End (Company Fiscal Year End)

Key Players & Entities

• Innoviva, Inc. (company) — Filer
• DEF 14A (filing) — Form Type
• 2024-04-29 (date) — Filing Date
• 2024-06-17 (date) — Period of Report
• 1350 Old Bayshore Highway, Suite 400, Burlingame, CA 94010 (address) — Business Address
• 000-30319 (filing_id) — SEC File Number
• Theravance Inc. (company) — Former Company Name
• Advanced Medicine Inc. (company) — Former Company Name

FAQ

Industry Context

Innoviva, Inc. operates in the Pharmaceutical Preparations industry.

Regulatory Implications

The DEF 14A filing is a requirement under the Securities Exchange Act of 1934 for public companies soliciting proxies from shareholders.

What Investors Should Do

1. Review executive compensation details and rationale.
2. Analyze any proposed amendments to corporate governance policies.
3. Understand the voting procedures and deadlines for shareholder proposals.

Key Dates

• 2024-04-29: Filing Date — Filing of Definitive Proxy Statement
• 2024-06-17: Period of Report — Reporting period for the proxy statement

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure for public companies regarding shareholder meetings and executive compensation, not a financial report with year-over-year performance comparisons.

Key Financial Figures

• $0.01 — f the Company's Common Stock, par value $0.01 per share (the "Common Stock"), outstan
• $20,000 — t a cost that is not expected to exceed $20,000 plus reasonable out-of-pocket expenses.

Filing Documents

• d492136ddef14a.htm (DEF 14A) — 607KB
• g492136g00a02.jpg (GRAPHIC) — 22KB
• g492136g00a03.jpg (GRAPHIC) — 27KB
• g492136g01n89.jpg (GRAPHIC) — 29KB
• g492136g15g15.jpg (GRAPHIC) — 399KB
• g492136g16g16.jpg (GRAPHIC) — 206KB
• g492136g46g01.jpg (GRAPHIC) — 122KB
• g492136g46g02.jpg (GRAPHIC) — 114KB
• g492136g47g01.jpg (GRAPHIC) — 116KB
• g492136g47g02.jpg (GRAPHIC) — 117KB
• 0001193125-24-122923.txt (&nbsp;) — 3960KB
• inva-20231231.xsd (EX-101.SCH) — 5KB
• inva-20231231_def.xml (EX-101.DEF) — 4KB
• inva-20231231_lab.xml (EX-101.LAB) — 7KB
• inva-20231231_pre.xml (EX-101.PRE) — 4KB
• d492136ddef14a_htm.xml (XML) — 192KB

From the Filing

DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 INNOVIVA, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. April 29, 2024 Dear Fellow Innoviva Stockholder: I am pleased to invite you to attend Innoviva, Inc.'s 2024 Annual Meeting of Stockholders (the "Annual Meeting"), to be held on June 17, 2024 at the offices of Willkie Farr & Gallagher LLP, 787 Seventh Avenue, New York, New York 10019. The Annual Meeting will begin promptly at 11:00 am, Eastern Time. Your Board of Directors (the "Board of Directors") is recommending a highly qualified, experienced and diverse slate of director nominees for election to the Board of Directors at the Annual Meeting. At the Annual Meeting, we will ask you to: (1) elect six directors; (2) cast a non-binding advisory vote to approve named executive officer compensation; (3) ratify the selection of Deloitte & Touche LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2024; and (4) take action upon any other business as may properly come before the Annual Meeting. The accompanying materials include the Notice of Annual Meeting of Stockholders and proxy statement (the "Proxy Statement"). The Proxy Statement describes the business that we will conduct at the Annual Meeting. It also provides information about us that you should consider when you vote your shares. Also enclosed with these proxy materials is a proxy card and postage-paid return envelope. Proxy cards are being solicited on behalf of our Board of Directors. Whether or not you will be able to attend the Annual Meeting, it is very important that your shares be represented. We urge you to read the accompanying Proxy Statement carefully and to use the enclosed proxy card to vote for the Board of Directors' nominees, and in accordance with the Board of Directors' recommendations on the other proposals, as soon as possible. You may vote your shares by signing and dating the enclosed proxy card and returning it in the postage-paid envelope provided, whether or not you plan to attend the Annual Meeting. For your convenience, you may also vote your shares via the Internet or by a toll-free telephone number by following the instructions on the enclosed proxy card. If your brokerage firm, bank, dealer or other similar organization is the holder of record of your shares ( i.e. , your shares are held in "street name"), you will receive voting instructions from the holder of record. You must follow these instructions in order for your shares to be voted. Your broker is required to vote those shares in accordance with your instructions. We urge you to instruct your broker or other nominee, by following those instructions, to vote your shares on the proxy card. Holders of shares as of the close of business on April 18, 2024, the record date for voting at the Annual Meeting, are urged to submit a proxy card, even if your shares were sold after such date. If you have any questions regarding this information or the proxy materials, please visit our website at www.inva.com or contact our investor relations department at investor.relations@inva.com. If you have any questions or need assistance voting your shares, please call D.F. King & Co., Inc., which is assisting Innoviva, Inc., toll free at (800) 290-6428. On behalf of your Board of Directors, thank you for your continued support and interest. Very truly yours, Pavel Raifeld Chief Executive Officer - 1 - Innoviva, Inc. 1350 Old Bayshore Highway, Suite 400 Burlingame, California 94010 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held On June 17, 2024 Dear Stockholder: You are cordially invited to attend the Annual Meeting of Stockholders of Innoviva, Inc., a Delaware corporation (the "Company"). The meeting will be held on Monday, June 17, 2024 at 11:00 a.m., Eastern Time, at the offices of Willkie Farr & Gallagher LLP, 787 Seventh Avenue, New York, New York 10019, for the following purposes: Proposal 1: To elect six directors to serve for the ensuing year. Proposal 2: To approve a non-binding advisory resolution regarding executive compensation. Proposal 3: To ratify the selection by the Audit Committ

View Full Filing

View this DEF 14A filing on SEC EDGAR